private markets

Local media reported Monday that Mumbai-based TechInvention has struck an import deal with EuBiologics to market the South Korean company’s oral cholera vaccine (OCV) in India.

Business Standard quoted TechInvention CEO Syed Ahmed as saying the move fills a market gap resulting from Sanofi’s OCV production pause at its Shantha subsidiary. TechInvention is targeting a price range for Euvichol-Plus of $8-$10 per single dose in India’s private market, according to the article. The company…